



## **Collegium to Present at Upcoming Investor Conferences**

November 12, 2018

STOUGHTON, Mass., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain, today announced that management will present at the following investor conferences in November:

- The Jefferies Healthcare Conference on Wednesday, November 14<sup>th</sup> at 4:00 p.m. GMT in London
- The Piper Jaffray Healthcare Conference on Tuesday, November 27<sup>th</sup> at 2:30 p.m. EST in New York City

### **About Collegium Pharmaceutical, Inc.**

Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain and our communities.

### **About Xtampza ER**

Xtampza® ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:

Alex Dasalla

[adasalla@collegiumpharma.com](mailto:adasalla@collegiumpharma.com)



Collegium Pharmaceutical, Inc.